Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-11-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess short and long term outcomes after radiofrequency ablation (RFA) combined with chemotherapy for pulmonary malignancies in patients who are not candidates for surgical resection. This study will evaluate the efficacy of RFA combined with chemotherapy for the treatment of lung tumors by assessing its impact on local tumor control, progression free survival, overall survival, dyspnea score and quality of life (QOL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00499447

Lung Cancer

COMPLETED NA

Study of Outcomes of Radiofrequency Ablation of Lung Tumors

NCT00280189

NSCLC Pulmonary Metastases

SUSPENDED

Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer

NCT00039507

Lung Cancer

COMPLETED PHASE2

Protocol for Radiofrequency Ablation of Pulmonary Neoplasms

NCT00232128

Pulmonary Neoplasms

TERMINATED NA

Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00109876

Lung Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Percutaneous image-guided RFA is a minimally invasive technique used to treat solid tumours. Because of its ability to produce large volumes of coagulation necrosis in a controlled fashion, this technique has gained acceptance as a viable therapeutic option for unresectable liver malignancies. Recently, RFA has been proposed as a viable option for the treatment of pulmonary malignancies. Experimental studies in animal tumor models have confirmed the effectiveness of RFA in the destruction of experimentally-induced pulmonary malignancies. Pilot clinical investigations have suggested that the treatment can achieve high proportions of tumor response. We designed a prospective clinical trial aimed at assessing feasibility, safety and effectiveness of RFA combined with chemotherapy in the treatment of lung malignancies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NSCLC Pulmonary Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiofrequency Ablation

Intervention Type PROCEDURE

Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiofrequency Ablation

Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

WHK-3 RFA (Welfare Electronics Co., Beijing PR China)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult (\> 18 years) male or female patient
* patient has biopsy-proven NSCLC or lung metastasis
* patient has been rejected for surgery and has been considered unfit for radiation therapy
* each 6 cm or smaller in greatest diameter of tumor, by CT scan
* tumors are located at least 1 cm from trachea; main bronchi; esophagus; aorta; aortic arch branches; pulmonary artery; and heart
* tumors are accessible by percutaneous route
* patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
* patient has platelet count \> 100 x 109 /L and international normalized ratio ≤ 1.5
* patient has signed written informed consent prior to any study specific procedures.

Exclusion Criteria

* patient is considered at high-risk for RF ablation due to major co-morbid medical conditions
* patient has more than 3 tumors / lung
* patient has at least one tumor \> 6 cm in greatest diameter
* tumor is associated with atelectasis or obstructive pneumonitis
* patient has renal failure requiring hemodialysis or peritoneal dialysis
* patient has active clinically serious infection
* patient has history of organ allograft
* patient has history of substance abuse or any medical, psychological or social conditions that may interfere with his / her participation in the study or evaluation of the study results
* patient is pregnant or breast-feeding
* patient has ECOG performance status \> 2
* patient has platelet count ≤ 100 x 109 /L or international normalized ratio \> 1.5.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No